







































Human Papillomavirus Seroprevalence and Seroconversion
Among Men Living With HIV: Cohort Study in South Africa
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Background: Men living with HIV (MLHIV) have a high
burden of human papillomavirus (HPV)-related cancer. Under-
standing serological dynamics of HPV in men can guide decisions
on introducing HPV vaccination and monitoring impact. We
determined HPV seroprevalence and evaluated factors associated
with HPV seroconversion among MLHIV in Johannesburg,
South Africa.
Methods: We enrolled 304 sexually active MLHIV 18 years and
older and collected sociobehavioral data, blood samples (CD4+
counts, HIV-1 plasma viral load, and HPV serology), and genital and
anal swabs [HPV DNA and HPV viral load (VL)] at enrollment and
6-monthly for up to 18 months. Antibodies to 15 HPV types were
measured using HPV pseudovirions. Generalized estimating equa-
tions were used to evaluate correlates of HPV seroconversion.
Results: Median age at enrollment was 38 years (IQR: 22–59), 25%
reported .1 sexual partner in the past 3 months, and 5% reported
ever having sex with other men. Most participants (65%) were on
antiretroviral therapy (ART), with median CD4+ count of 445
cells/mL (IQR: 328–567). Seroprevalence for any HPV type was
66% (199/303). Baseline seropositivity for any bivalent (16/18),
quadrivalent (6/11/16/18), and nonavalent (6/11/16/18/31/33/45/
52/58) vaccine types was 19%, 37%, and 60%, respectively. At
18 months, type-specific seroconversion among 59 men whose
genital samples were HPV DNA positive but seronegative for the
same type at enrollment was 22% (13/59). Type-specific sero-
conversion was higher among men with detectable HIV plasma
viral load (adjusted odds ratio = 2.78, 95% CI: 1.12 to 6.77) and
high HPV VL (adjusted odds ratio = 3.32, 95% CI: 1.42 to 7.74).
Conclusions: Seropositivity and exposure to nonavalent HPV
types were high among MLHIV. HPV vaccination of boys before
they become sexually active could reduce the burden of HPV
infection among this at-risk population.
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INTRODUCTION
Men living with HIV (MLHIV) have a high burden of
human papillomavirus (HPV) infections and related diseases,
such as anal and oropharnygeal cancers as well as anogenital
warts.1,2 Although antiretroviral therapy (ART) attenuates
risks of some sequelae of HPV infections, MLHIV remain
a risk of these diseases and some evidence even suggests an
increase in anal and oropharyngeal cancers.3,4 Therefore, they
are an important target group to consider when planning HPV
prevention strategies.
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HPV vaccines have been produced with bi/quadrivalent
(16/18) and nonavalent (16/18/31/33/45/52/58) vaccines esti-
mated to protect against 70% and 90% of cancer-causing high-
risk (HR) infections.5–7 However, because of the World Health
Organization’s (WHO) recommendation that limited public
health funds should be directed primarily toward achieving
a high coverage among girls to prevent cervical cancer, in most
low- and middle-income countries, HPV vaccines are only
routinely provided to girls.8,9
Natural infection with HPV can elicit immunoglobulin
G antibodies to the L1 capsid protein of the HPV viral
envelope known as a serological response.10 The potential
protective effect of naturally acquired type-specific antibodies
against subsequent infection with same-type HPV among
men is uncertain.11 A systematic review based on 3 studies,
all conducted in high-income countries, suggested that there
was no protective effect among men.12,13 However, more data
are needed, particularly in low- to middle-income countries.12
A better understanding of HPV type-specific serological
responses to natural infection in MLHIV and the risk of
subsequent infection is important in guiding targeted HPV
control efforts such as vaccination. This information, espe-
cially if gathered before widespread vaccine introduction,
could help improve our understanding of the HPV serological
dynamics among this group and be useful for monitoring
vaccine effectiveness and understanding of the impact of
vaccination programs among vulnerable populations over
time. It could also help account for any protection (if at all)
after natural infection when modeling future impacts of the
HPV vaccination programs.14
To address these knowledge gaps, we followed a cohort
of predominately heterosexual MLHIV in South Africa. We
estimated the HPV seroprevalence and concordance with
same-type DNA at enrollment in the cohort, evaluated HIV
and HPV virological factors associated with HPV serocon-
version at follow-up 18 months later, and explored the risk of
HPV DNA incident infection among men seropositive for the
same type at enrollment.
METHODS
Study Design, Population, and Data Collection
This cohort study has been described previously.15
Briefly, 304 HIV-1–seropositive men (MLHIV) aged 18
years or older who reported sexual activity in the past 3
months were recruited from ART clinics in inner-city
Johannesburg, South Africa. After enrollment, participants
were followed up every 6 months for up to 18 months. An
interviewer-administered questionnaire was used to collect
data on sociodemographic, behavioral, and clinical char-
acteristics. Furthermore, to optimize privacy, participants
completed sensitive questions on sexual behavior using
a computer-assisted self-interview.
Sample Collection
At each visit, venous blood was collected to test for
CD4+ cell count (FACScount, BD; BD Biosciences, San Jose,
CA); HIV-1 plasma viral load (PVL) using Roche Taqman
(Roche Diagnostics, Mannheim, Germany) and HPV serol-
ogy. A genital sample for HPV DNA testing was collected by
rubbing a cotton swab around the glans penis, coronal sulcus,
and ventral surface of the penis as previously described.15 An
anal sample for HPV DNA testing was collected by blindly
(ie, without anoscopy) inserting a Dacron swab 3 centimeters
into the anal canal and removing it while rotating and
applying pressure on the walls of the canal. Swabs were
stored at 270°C before HPV DNA testing.
Laboratory Testing
HPV detection and genotyping were performed using
an identical method at enrollment and at last follow-up visit.
The MagNA Pure LC DNA Isolation Kit I (Roche Diag-
nostics) was used to extract HPV DNA from the swabs. HPV
genotype distributions were then assessed by the Roche
Linear Array assay (RLA; Roche Diagnostics). HPV16 and
HPV18 genital viral loads (VL, copies per million human
cells) were quantified at enrollment on samples that were
positive for these types using quantitative duplex real-time
PCR method.16 Genital and anal samples were tested
separately. This method allows the HPV16, HPV18, and
albumin gene copy number to be quantified in the same assay.
The human b-globin gene served as an internal control for
cellular adequacy and extraction efficiency. For the purposes
of this analysis, HPV DNA positivity was limited to the 15
types covered by the serology assay (HPV6/11/16/18/31/33/
35/39/45/52/56/58/59/68/73) with HR-HPV being similarly
defined with the following 12 types: HPV16/18/31/33/35/39/
45/52/56/58/59/68.17
HPV antibodies were detected using a multiplexed
binding assay and classified as seropositive or seronegative
based on the preassigned cutoff. This uses pseudovirions
(PsV) as antigens and detects HPV type-specific immuno-
globulin G antibodies (PsV-Luminex). Serology was
performed to detect the following HR types HPV16/18/
31/33/35/39/45/52/56/58/59/68 and the low-risk (LR) types
HPV6/11/73 at Karolinska Institute, Stockholm, Swe-
den.18,19 Serum samples were analyzed in 1:50 and 1:150
dilutions. Seropositivity cutoff values were independently
determined for each HPV type by analyzing the mean
fluorescence intensity unit (MFI) values obtained from
a panel of 100 children’s sera (#12 years old and presumed
virgins). The cutoff algorithm was as recommended by the
global HPV LabNet (mean MFI value of a negative control
serum panel plus 3 SDs).20 In cases where the cutoff value
was unexpectedly low (ie, ,400 MFI), 400 MFI was used
as cutoff to have a sensitivity and specificity similar to
classical HPV ELISAs.21
Definition of HPV DNA and Serology Status
HPV DNA Status
Genital swab results were used to determine the HPV
DNA status. There were more genital samples (304) as only
250 (82%) men accepted anal swabbing. Men were
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considered “HPV DNA positive” if positive by RLA for
any of the HPV types included in the serology assay, and
“HPV DNA negative” if negative for all these types. HPV
DNA genotype-specific persistence was defined as being
positive for the same type at enrollment and 18-month visit.
Type-specific clearance was defined as being positive for
a specific type at enrollment and negative for that type at
18-month visit.
HPV Serology Status
Overall and type-specific or group (ie, vaccine targets)
HPV seroprevalences were defined as being seropositive for
any/type-specific/grouped types, respectively. HPV type-
specific seroconversion was defined as being HPV DNA
positive and same-type seronegative at enrollment that
became same-type seropositive at 18-month visit, regardless
of the HPV DNA status at 18-month visit. We also
computed type-specific seropersistence (having same-type
detectable antibody at enrollment and 18-month visit)
among all men who were seropositive for any HPV type at
enrollment, and calculated seroincidence (seronegative for
a specific HPV type at enrollment and seropositive for the
same type at 18-month visit) among all men who were
seronegative at enrollment, irrespective of their HPV
DNA status.
Statistical Analysis
To compare HPV seropositivity among type-specific
HPV DNA positive and DNA negative MLHIV at enroll-
ment, prevalence ratios (PRs) were obtained from logistic
regression using marginal standardization and the accompa-
nying 95% confidence intervals (CI) were estimated using the
delta method.22 Factors associated with HPV seroconversion
were explored using generalized estimating equations to
account for seropositivity by multiple types within MLHIV
and presented as adjusted odds ratios (OR) and their 95%
CI.23 To explore HIV-related factors associated with HPV
seroconversion, preplanned analyses included stratification by
ART status (ART or no ART), ART duration (#1 or .1
year) and CD4+ cell counts/mL at enrollment (,200,
201–350, 351–500, .500), and HIV-1 PVL (plasma HIV-1
RNA ,40 or $40 copies/mL) at enrollment. Stable high
CD4+ count was defined as having CD4+ counts .500
cells/mL at all 3 follow-up visits. Sustained HIV virological
control was defined as HIV-1 PVL ,40 copies/mL at all
the 3 follow-up visits. Controlled disease status was
defined as being on ART for .6 months, CD4+ .350
cells/mL, and HIV-1 RNA ,40 copies/mL. High HPV VL
was defined as viral load . 5.3 log10/106 cells as pre-
viously described.16 Multivariable analyses were adjusted
for sociodemographic and behavioral factors which were
associated with HPV seroconversion at bivariate analysis at
P , 0.10.24 Risk ratios (RRs) were calculated to explore
the association between HPV seropositivity at enrollment
and HPV DNA infection incidence at 18-month follow-up.
Data were analyzed using Stata version 15 (Stata Statistical
Software; Stata Corporation, College Station, TX).
Ethics Statement
Ethical approval for the study was obtained from the
Wits Human Research Ethics Committee (reference numbers:
M111191 and M160859). All study participants provided
written, informed consent after explanation of the study
objectives and testing procedures.
RESULTS
Study Population
A detailed description of the cohort is provided
elsewhere.15 Of the 304 MLHIV enrolled, the median age
at enrollment was 38 years (IQR: 22–59), 25% reported .1
sexual partner in the past 3 months, and 5% reported ever
having sex with other men. At enrollment, most participants
(65%) were on ART, with median CD4+ count of 445 cells/
mL (IQR: 328–567), and 54% were virologically suppressed
(plasma HIV RNA ,40 copies/mL).
HPV Seroprevalence at Enrollment
Enrollment HPV serology results were available for
99% (303/304) of the enrolled men. Seroprevalence of any
HPV type was 66% (199/303), of whom 67% (134/199) were
seropositive for multiple (ie, .1) types. The seroprevalence
of any 12 HR-HPV types was 61%. For the HR types,
seroprevalence was highest for HPV58 (30%), followed by
HPV52 (27%) and HPV35 (18%). Seropositivity for any
HPV types of the bivalent (HPV16/18), quadrivalent (HPV6/
11/16/18), and nonavalent (HPV6/11/16/18/31/33/45/52/58)
vaccine types was 19%, 37%, and 60%, respectively. No
participants were seropositive for all HPV types included in
the nonavalent vaccine (Fig. 1).
Relationship Between HPV DNA and HPV
Antibody-Specific Prevalence at Enrollment
Of the 184/257 (71%) men who were HPV DNA
positive for any of the 15 HPV types at enrollment (“HPV
DNA positive”), 125 (68%) were seropositive for the same
HPV type at enrollment (ranging by type from 0% for HPV73
(0/12) to 50% for HPV31 (3/6); Table 1). The type-specific
HPV seroprevalence was significantly higher among those
with same-type HPV DNA positive compared with same-type
DNA negative for the HR types HPV31 after adjusting for
employment status and age at sexual debut [adjusted
prevalence ratio (aPR) = 4.31; 95% CI: 1.80 to 10.31],
HPV45 (aPR = 3.68; 95% CI: 1.07 to 12.68), HPV59 (aPR =
2.29; 95% CI: 1.86 to 6.10), and LR types HPV6 (aPR =
2.75; 95% CI: 1.65 to 4.57) and HPV11 (aPR = 3.73; 95% CI:
1.90 to 7.32; Table 1).
HPV Seroconversion and Association With
DNA Persistence and Clearance
A total of 59 MLHIV were HPV DNA positive and
same-type seronegative at enrollment. Among these 59, 13
(22%) seroconverted for their type(s), giving a total of 18
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seroconversions events (5 men had .1 type-specific sero-
conversion event). Type-specific seroconversion was highest
for HPV58 (29%) and HPV16 (22%) while there were no
seroconversion events for the HR types 31, 33, and 45.
Overall, type-specific seroconversion was more frequent with
same-type cleared DNA infection compared with persistent
infection (any HPV type seroconversion: 33% versus 27%;
P value = 0.03; Table 2).
HIV-Related Factors Associated With
HPV Seroconversion
The risk of seroconversion was higher among MLHIV
with detectable HIV PVL at enrollment compared to those
with undetectable HIV PVL after adjusting for employment
status and age at sexual debut [adjusted odds ratio (aOR) =
2.78, 95% CI: 1.12 to 6.77, P value = 0.03]. Similarly, there
was a higher risk of seroconversion among men who had high
enrollment HPV18 viral load (#5.3 log10 vs. .5.3 log10/
106cells; aOR = 3.32, 95% CI: 1.42 to 7.74, P value = 0.01).
There was marginal evidence that MLHIV who were less than
a year on ART were more likely to seroconvert compared
with those at least one year on ART (aOR = 6.21, 95% CI:
0.76 to 50.8, P value = 0.09). CD4+ cell count, clearance of
genital HPV infection at 18 months, and anal HPV infection
status at enrollment were not independently associated with
seroconversion (Table 3).
Incident HPV DNA Infection, Seroincidence,
and Seropersistence Over 18 Months
We further evaluated the impact of baseline seropre-
valence status on incident HPV DNA infections during
18-month follow-up. There were only 6 incident genital
HPV DNA infections among the 119 MLHIV who were
negative for any of the 15 HPV DNA infection types at
enrollment. These were distributed as 4 infections among 74
men who were seropositive for any of the 15 types and 2
infections among the 45 men seronegative for all the 15
types. There was no significant difference in incidence of
HPV DNA infection between these 2 groups (risk ratio of
incident infection among those HPV seropositive at baseline
compared with those seronegative was RR = 1.21, 95% CI:
0.23 to 6.30, P value = 0.59; see Supplementary Table 1,
Supplemental Digital Content, http://links.lww.com/QAI/
B444). Among the 83 men who were seronegative for any
HPV type at enrollment, 28 (34%) had seroincidence
(seronegative for a specific HPV type at enrollment and
seropositive for the same type at 18-month visit). A total of
148 (89%) among the 167 men with detectable antibodies at
enrollment had seropersistence (having same-type detect-
able antibody at enrollment and 18-month visit) (see
Supplementary Table 2, Supplemental Digital Content,
http://links.lww.com/QAI/B444).
DISCUSSION
In this cohort study of predominantly heterosexual African
MLHIV, we report an overall HPV seroprevalence of 66%, and
60% for the nonavalent vaccine types. Although there are
difficulties in directly comparing these findings with previous
studies due to differences in the methods, serotypes assessed,
sexual behavior, and HIV status, these levels are higher than in
most previous studies. For instance, the seroprevalence of
quadrivalent vaccines types of 37% that we found is much
higher than 13% and 21% reported among HIV-negative men in
the United States.25,26 Similarly, the seroprevalence of non-
avalent vaccines types is 3-fold higher than the 20% reported
FIGURE 1. HPV seroprevalence* any
HPV type prevalence defined as
positive for at least one HPV type (6/
11/16/18/31/33/35/39/45/52/56/
58/59/68/73) at enrollment; any
HR-HPV type prevalence defined as
positive for at least one HR-HPV
type (16/18/31/33/35/39/45/52/
56/58/59/68) at baseline; any 9V =
positive for any of HPV6/11/16/18/
31/33/45/52/58 (nonavalent HPV
vaccine); any 9V-HR = positive for
any of HPV16/18/31/33/45/52/58;
any 4V = positive for any of HPV6/
11/16/18 (quadrivalent HPV vac-
cine); any 4V-LR = positive for any
of HPV6/11; any 2V = positive for
any of HPV16/18 (bivalent HPV
vaccine); all 9V = positive for all of
HPV6, 11, 16, 18, 31, 33, 45, 52,
and 58; all 9V-HR = positive for all
of HPV16, 18, 31, 33, 45, 52, and
58; all 4V = positive for all of HPV6,
11, 16, and 18; all 2V = positive for
BOTH HPV16 and 18; all 4V-LR =
positive for BOTH HPV 6 and 11.
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among HIV-negative men in the United States, but similar to the
61% reported among HIV-positive men who have sex with men
in Amsterdam, the Netherlands.11,27
Our analysis showed that almost 70% of men with
HPV DNA infection at baseline were seropositive. This is
keeping with previous reports that L1 seroconversion does
not always occur after sexually transmitted HPV infec-
tion.28,29 Although the reason for this observation is
unclear, it may be because the humoral response against
HPV L1 capsid protein is very weak, thus unmeasurable
with the current serological tests. Previous studies have
reported that men have a considerably lower HPV sero-
prevalence than women,30,31 and a recent study suggested
that HPV-seropositive women may have higher antibody
levels than HPV-seropositive men.32 This may be because
HPV infections in women have more access to the mucosal
immune system than HPV infections on the keratinized
surface of the male genitals.12
We found that HPV seroconversion was associated with
detectable HIV PVL and higher genital HPV viral load. This

























HPV6 34 14 41.2 223 34 15.3 2.75 (1.65
to 4.57)
HPV11 18 8 44.4 239 27 11.3 3.73 (1.90
to 7.32)
HPV16† 28 5 17.9 229 39 17.0 1.09 (0.47
to 2.54)





HPV31† 6 3 50.0 251 30 12.0 4.31 (1.80
to 10.31)
HPV33† 11 3 27.3 246 27 11.0 2.54 (0.90
to 7.14)
HPV45† 20 3 25.0 237 9 3.8 3.68 (1.07
to 12.68)
HPV52† 17 6 35.3 240 63 26.3 1.34 (0.68
to 2.65)
HPV58† 20 6 30.0 237 68 28.7 0.91 (0.42
to 1.99)
Nonvaccine types
HPV35† 32 5 15.6 225 39 17.3 0.92 (0.39
to 2.16)
HPV39† 12 1 8.3 245 20 8.2 0.89 (0.13
to 6.26)
HPV56† 10 1 10.0 247 14 5.7 1.65 (0.24
to 11.56)
HPV59† 21 5 23.8 236 20 8.5 2.29 (1.86
to 6.10)
HPV68† 20 3 15.0 237 14 5.9 2.27 (0.83
to 8.79)
HPV73 12 0 0.0 245 4 1.6 —




117 78 66.7 140 80 57.5 1.16 (0.97
to 1.40)
*Adjusted prevalence ratio [PR] from logistic regression using marginal standardization for type-specific seroprevalence if same-type DNA positive compared with DNA negative,
adjusted for employment status and age at sexual debut.
†Denotes high-risk (HR) HPV types.
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is probably related to the fact that a higher HPV viral load is
required to induce a measurable type-specific serum antibody
response against epitopes of the HPV L1 capsid protein. This
is also aligned with our finding that HPV seroconversion was
more common among MLHIV who had cleared HPV DNA,
perhaps indicating the important role of a competent immune
system in seroconversion and the subsequent clearance of
HPV infection.
Our results show that HPV seropositivity at baseline
was not protective of type of incident infection at 18
months. Although this finding need to be interpreted with
caution owing to the small sample size, it is consistent with
the conclusions of a systematic review that naturally
acquired HPV antibodies are not protective of subsequent
HPV infections among men.12 The reasons for this are not
fully understood. However, it has been hypothesized that
the observed HPV DNA infections are probably a combi-
nation of newly acquired, reactivated latent and transient
infections.33 Although the currently available commercial
PCR-based assay methods cannot distinguish between
a potential acquisition versus a reactivation, new evidence
supports the hypothesis that natural immunity protects
against new acquisition but not reactivation.34 Protection
against new HPV infections is believed to be largely
antibody mediated immunity, whereas control of existing
infections is probably more cell-mediated. It is therefore
plausible that protection from serum antibodies is only
a surrogate marker for other local mechanisms that may
still need further elucidation.12
This cohort study was limited by the fact that HPV
serology and HPV DNA were only tested at 2 time points
(enrollment and 18 months). It is therefore difficult to
determine whether the specific seroconversion events
occurred in response to either an infection which persisted
during follow-up or a prevalent HPV infection at enrollment
which was cleared followed by same-type reinfection or
reactivation of a latent infection (ie, transient infections).
Similarly, when evaluating the risk of reinfection according to
same-type seropositivity at baseline, we cannot be certain if
the HPV DNA infection detected at 18-month follow-up was
TABLE 2. Type-Specific Seroconversion at 18 Months Among 59 MLHIV Who Were DNA Positive and Seronegative at Enrollment
















N Infections n (%)* N Infections n (%)† N Infections n (%)‡
Bivalent/
quadrivalent
HPV6 20 1 (1.5) 2 0 (0.0) 18 1 (5.6)
HPV11 10 2 (20.0) 1 0 (0.0) 9 2 (22.2)
HPV16§ 23 5 (21.7) 7 2 (28.6) 16 3 (18.8)
HPV18§ 19 2 (10.5) 0 0 (0.0) 19 2 (10.5)
Additional
nonavalent
HPV31§ 3 0 (0.0) 0 0 (0.0) 3 0 (0.0)
HPV33§ 8 0 (0.0) 1 0 (0.0) 7 0 (0.0)
HPV45§ 17 0 (0.0) 1 0 (0.0) 16 0 (0.0)
HPV52§ 11 1 (9.1) 1 0 (0.0) 10 1 (10.0)
HPV58§ 14 4 (28.6) 0 0 (0.0) 14 4 (30.8)
Nonvaccine
HR-HPV
HPV35§ 27 2 (7.4) 1 0 (0.0) 26 2 (7.8)
HPV39§ 11 0 (0.0) 2 0 (0.0) 9 0 (0.0)
HPV56§ 9 0 (0.0) 0 0 (0.0) 9 0 (0.0)
HPV59§ 16 0 (0.0) 5 0 (0.0) 11 0 (0.0)
HPV68§ 17 0 (0.0) 2 0 (0.0) 15 0 (0.0)
Nonvaccine
LR-HPV
HPV73 12 1 (8.3) 4 0 (0.0) 8 1 (12.5)
Any HPV 59 13 (22.2) 26 2 (7.7) 33 11 (33.3)
Any HR-
HPV§
39 11 (28.2) 6 2 (33.3) 33 9 (27.3)
*Seroconversion calculated among 59 men with DNA positive and antibody negative status at enrollment.
†Seroconversion calculated among men with DNA positive and antibody negative at baseline and with type-specific persistence at 18 months.
‡Seroconversion calculated among men with DNA positive and antibody negative at baseline and type-specific clearance at 18 months.
§High-risk (HR) HPV types (NOTE: the total is not the sum of individual infections, but only infected men, some having .1 infection).
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a new acquisition or a reactivation of a latent infection.
Moreover, the low incidence of HPV DNA infections made
exploring the impact naturally acquired antibodies have on
incident infections challenging, and thus, the results presented
need to be interpreted with caution. Despite these limitations,
our study also has several strengths which include its
longitudinal design, the availability of serology and HPV
DNA genotyping data of 15 serotypes at both enrollment and
18 months. This is also the first study to explore HPV
seroepidemiology using longitudinal data among MLHIV
in Africa.
CONCLUSIONS
Overall seropositivity and exposure to nonavalent HPV
types was high among MLHIV. The lack of protection from
naturally acquired infection supports the hypothesis that HPV
vaccination of boys before they become sexually active could
reduce the burden of HPV infection and related disease
among this population. The high seroprevalence of the
nonavalent types supports the need to make this multivalent
vaccine more widely available.
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